Company Overview and News
WallStars show positive broker target price-upsides. 66 displayed 10%+ forward yield, at $2+ prices, and $10M+ market caps as of 8/9/18. Yields above 11.88% narrowed this WallStar list to 30.
SNR.WI NGL SNR AIC MCQ MMLP MCV BBDC PER HCLP SNR MCX AI GMLP MDLY CVRR AIW SNMP MCC
In its August 2018 edition, The Utility Forecaster warns readers to approach MLPs “with caution.” Too risky for income investors is their conclusion. MLP buyers have been badly abused, and Chief Investment Strategist Robert Rapier reminds readers of the many “simplifications” that triggered unwelcome tax bills, as well as the multiple distribution cuts. Without doubt, MLP prices have followed distributions.
AMID KMI KMR KMRFZ CVB HCLP
HOUSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Hi-Crush Partners LP (NYSE: HCLP), or “Hi-Crush”, today announced that management will present and meet with investors at the following investor conferences:
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Greetings, and welcome to the Hi-Crush Partners LP Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
The following slide deck was published by Hi-Crush Partners LP in conjunction with their 2018 Q2 earnings call.
Hi-Crush Partners LP (HCLP - Free Report) reported net income of $68 million or 67 cents per share in second-quarter 2018, up from $16.4 million or 18 cents in the year-ago quarter. However, earnings missed the Zacks Consensus Estimate of 77 cents. Revenues surged roughly 83.8% year over year to $248.5 million, driven by improved pricing and increased volumes. The figure narrowly missed the Zacks Consensus Estimate of $248.
KMG NGVT NGVT.WI CE HCLP
HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Hi-Crush Partners LP (NYSE: HCLP), "Hi-Crush" or the "Partnership", today reported second quarter 2018 results. Revenues for the second quarter of 2018 totaled $248.5 million on sales of 3,037,504 tons of frac sand. This compares to $218.1 million of revenues on sales of 2,617,627 tons of frac sand in the first quarter of 2018. The limited partners' interest in net income was $60.
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...
as of ET